ACADEMIC AND RESEARCH PEER-REVIEWED MEDICAL JOURNALISSN 1727-2378 (Print)         ISSN 2713-2994 (Online)
Ru
En

Preventive Vaccination against Cervical Cancer and HPV-associated Disorders: International and National Data

Bibliography link: Zarochentseva N. V., Belaya Yu. M., Dzhidzhikhiya L. K. Preventive Vaccination against Cervical Cancer and HPV-associated Disorders: International and National Data. Doctor.Ru. 2018; 2(146): 52–58.
20 February 12:30

Objective of the Review: To describe the latest international and Russian data on the use of preventive vaccination against cervical cancer (CC) and HPV-associated disorders.

Key Points: According to the World Health Organization, HPV infection is the main trigger for the development of cancer of the cervix, vulva, vagina, perianal and oropharyngeal areas in both men and women, and cancer of the male genital organs. Approximatively 15,000–16,000 new cases of CC and more than 7,000 deaths are reported annually in the Russian Federation. In addition to screening, primary prevention of HPV-associated disorders is currently available worldwide. About 30 regional programs have been established in Russia so far; Moscow Region is one of the first regions to have implemented a successful preventive vaccination program, beginning in 2008. Substantial experience has been accumulated, and the effectiveness of such vaccination has been confirmed.

Conclusion: International and Russian experience with preventive vaccination against CC and HPV-associated disorders confirms its high levels of effectiveness and safety.

N. V. Zarochentseva — Moscow Regional Research Institute for Obstetrics and Gynecology. M. F. Vladimirsky Moscow Regional Clinical Research Institute. E-mail: ninazar11@mail.ru

Yu. M. Belaya — Moscow Regional Research Institute for Obstetrics and Gynecology. E-mail: belajay@yandex.ru

L. K. Dzhidzhikhiya — Moscow Regional Research Institute for Obstetrics and Gynecology. E-mail: lel3311@yandex.ru


Доктор.ру
20 February 12:30
LITERATURE
  1. Роговская С. И., Теребнева Л. И. Клинические аспекты плоскоклеточных интраэпителиальных поражений низкой степени. Акушерство и гинекология. 2013; 2: 139–43. [Rogovskaya S. I., Terebneva L. I. Klinicheskie aspekty ploskokletochnykh intraepitelial'nykh porazhenii nizkoi stepeni. Akusherstvo i ginekologiya. 2013; 2: 139–43. (in Russian)]
  2. Подзолкова Н. М., Созаева Л. Г., Осадчев В. Б. Папилломавирусная и герпетическая инфекции в акушерстве и гинекологии. Учебно­методическое пособие. М.; 2007. 46 с. [Podzolkova N. M., Sozaeva L. G., Osadchev V. B. Papillomavirusnaya i gerpeticheskaya infektsii v akusherstve i ginekologii. Uchebno­metodicheskoe posobie. M.; 2007. 46 s. (in Russian)]
  3. Ашрафян Л. А., Киселев В. И. Опухоли репродуктивных органов. М.: изд­во Дмитрейд График Групп; 2008: 216 с. [Ashrafyan L. A., Kiselev V. I. Opukholi reproduktivnykh organov. M.: izd­vo Dmitreid Grafik Grupp; 2008: 216 s. (in Russian)]
  4. Poljak M., Rogovskaya S. I., Kesic V., Bray F., Berkhof J., Seme K. et al. Recommendations for cervical cancer pevention in Central and Eastern Europe and Central Asia. Vaccine. 2013; 31(suppl.7): H80–82.
  5. Bruni L., Barrionuevo­Rosas L., Albero G., Serrano B., Mena M., Gómez D. et al. Human papillomavirus and related diseases report. http://www.hpvcentre.net/statistics/reports/XWX.pdf (дата обращения — 15.01.2018).
  6. Bruni L., Barrionuevo­Rosas L., Albero G., Serrano B., Mena M., Gómez D. et al. Russian Federation: human papillomavirus and related diseases report. http://www.hpvcentre.net/statistics/reports/RUS.pdf (дата обращения — 15.01.2018).
  7. Каприн А. Д., Старинский В. В., Петрова Г. В., ред. Состояние онкологической помощи населению России в 2015 году. М.: МНИОИ им. П. А. Герцена; 2016. 236 с. [Kaprin A. D., Starinskii V. V., Petrova G. V., red. Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2015 godu. M.: MNIOI im. P. A. Gertsena; 2016. 236 s. (in Russian)]
  8. Свирская С. В., Егорова А. Т. Современное состояние проблемы заболеваемости и инвалидности у женщин, больных раком шейки матки. Сиб. мед. обозрение. 2011; 3: 3–8. [Svirskaya S. V., Egorova A. T. Sovremennoe sostoyanie problemy zabolevaemosti i invalidnosti u zhenshchin, bol'nykh rakom sheiki matki. Sib. med. obozrenie. 2011; 3: 3–8. (in Russian)]
  9. Kyrgiou M., Koliopoulos G., Martin­Hirsch P., Arbyn M., Prendiville W., Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta­analysis. Lancet. 2006; 367(9509): 489–98.
  10. Giuliano A. R., Lazcano E., Villa L. L., Flores R., Salmeron J., Lee J. H. et al. Circumcision and sexual behavior: factors independently associated with human papillomavirus detection among men in the HIM study. Int. J. Cancer. 2009; 124(6): 1251–7.
  11. Garland S. M., Kjaer S. K., Muñoz N., Block S. L., Brown D. R., DiNubile M. J. et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real­world experience. Clin. Infect. Dis. 2016; 63(4): 519–27.
  12. Зароченцева Н. В., Белая Ю. М. Современный взгляд на остроконечные кондиломы: возможности лечения и профилактики. Рос. вестн. акушера­гинеколога. 2017; 17(1): 109–12. [Zarochentseva N. V., Belaya Yu. M. Sovremennyi vzglyad na ostrokonechnye kondilomy: vozmozhnosti lecheniya i profilaktiki. Ros. vestn. akushera­ginekologa. 2017; 17(1): 109–12. (in Russian)]
  13. Drolet M., Bénard É., Boily M. C., Ali H., Baandrup L., Bauer H. et al. Population­level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta­analysis. Lancet Infect. Dis. 2015; 15(5): 565–80.
  14. Immunise Australia Program. Australian Government Department of Health. http://www.health.gov.au/internet/immunise/publishing.nsf/Content/immunise­hpv (дата обращения — 15.01.2018).
  15. Garland S. M., Bhatla N., Ngan H. Y. Cervical cancer burden and prevention strategies: Asia Oceania perspective. Cancer Epidemiol. Biomarkers Prev. 2012; 21(9): 1414–22.
  16. European Centre for Disease Prevention and Control. Introduction of HPV vaccines in European Union countries — an update. Stockholm: ECDC; 2012. 40 p.
  17. Baandrup L., Blomberg M., Dehlendorff C., Sand C., Andersen K. K., Kjaer S. K. Sex Transm. Dis. 2013; 40(2): 130–5.
  18. Stokley S., Jeyarajah J., Yankey D., Cano M., Gee J., Roark J. et al; Human papillomavirus vaccination coverage among adolescents, 2007–2013, and postlicensure vaccine safety monitoring, 2006–2014 — United States. MMWR Morb. Mortal Wkly. Rep. 2014; 63(29): 620–4.
  19. German Standing Committee on Vaccination (STIKO) recommendations, 2014. Robert Koch Institute. https://www.rki.de/EN/Content/infections/Vaccination/recommandations/recommendations_node.html (дата обращения — 15.01.2018).
  20. Poethko­Müller C., Buttmann­Schweiger N; KiGGS Study Group. [HPV vaccination coverage in German girls: results of the KiGGS study: first follow­up (KiGGS Wave 1)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014; 57(7): 869–77.
  21. Canada Communicable Disease Report 2012. http://www.phac­aspc.gc.ca/publicat/ccdr­rmtc/12vol38/acs­dcc­1/index­eng.php#a1 (дата обращения — 15.01.2018).
  22. Centers for Disease Control and Prevention. Human papillomavirus. HPV Vaccine Coverage Maps — Infographic/ https://www.cdc.gov/hpv/infographics/vacc­coverage.html (дата обращения — 15.01.2018).
  23. Leval A., Herweijer E., Ploner A., Eloranta S., Fridman Simard J., Dillner J. et al. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. J. Natl. Cancer Inst. 2013; 105(7): 469–74.
  24. Baldur­Felskov B., Dehlendorff C., Munk C., Kjaer S. K. Early impact of human papillomavirus vaccination on cervical neoplasia — nationwide follow­up of young Danish women. J. Natl. Cancer Inst. 2014. 106(3): djt460.
  25. HPV vaccination coverage 2015. National HPV Vaccination Program Register. http://www.hpvregister.org.au/site/DefaultSite/filesystem/documents/Coverage­Data/2017/Coverage%20by%20dose%202015%20­%20females.pdf (дата обращения — 15.01.2018).
  26. New Zealand Ministry of Health. HPV immunisation programme. http://www.health.govt.nz/our­work/preventative­health­wellness/immunisation/hpv­immunisation­programme (дата обращения — 15.01.2018).
  27. Statens Serum Institut. Epi­news about diseases and vaccines. http://www.ssi.dk/English/News/EPI­NEWS/2017/No%2015­17%20­%202017.aspx (дата обращения — 15.01.2018).
  28. Markowitz L. E., Tsu V., Deeks S. L., Cubie H., Wang S. A., Vicari A. S. et al. Human papillomavirus vaccine introduction — the first five years. Vaccine. 2012; 30(suppl. 5): F139–48.
  29. Uhnoo I. Register­based monitoring of the Swedish HPV vaccination program. https://www.fhi.no/globalassets/migrering/dokumenter/pdf/register­based­monitoring­of­the­swedish­hpv­vaccination­programme.pdf (дата обращения — 15.01.2018).
  30. Reagan­Steiner S., Yankey D., Jeyarajah J., Elam­Evans L. D., Curtis C. R., MacNeil J. et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years — United States, 2015. MMWR Morb. Mortal Wkly. Rep. 2016; 65(33): 850–8.
  31. Robert Koch Institute. Epidemiologisches Bulletin. German Standing Committee on Vaccination (STIKO) recommendations, 24 August 2015. http://www.rki.de/EN/Content/infections/Vaccination/recommandations/34_2015_engl.pdf?__blob=publicationFile (дата обращения — 15.01.2018).
  32. Public Health Agency of Canada. Canadian Immunization Guide. https://www.canada.ca/en/public­health/services/publications/healthy­living/canadian­immunization­guide­part­1­key­immunization­information/page­13­recommended­immunization­schedules.html (дата обращения — 15.01.2018).
  33. Pan American Health Organization. Progress toward implementation of human papillomavirus vaccination — the Americas, 2006–2010. Washington, DC: PAHO; 2011.
  34. Statens Serum Institut. Novel HPV vaccine in the national childhood vaccination programme. January 20, 2016. http://www.ssi.dk/English/News/News/2016/2016%20­%2001%20­%20EPI­NEWS%202%20HPV.aspx (дата обращения — 15.01.2018).
  35. Luostarinen T., Apter D., Dillner J., Eriksson T., Harjula K., Natunen K. et al. Vaccination protects against invasive HPV­associated cancers. Int. J. Cancer. 2017; [Epub. ahead of print].
  36. Hariri S., Bennett N. M., Niccolai L. M., Schafer S., Park I. U., Bloch K. C. et al. Reduction in HPV 16/18­associated high grade cervical lesions following HPV vaccine introduction in the United States — 2008–2012. Vaccine. 2015; 33(13): 1608–13.
  37. McCormack P. L. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts. Drugs. 2014; 74(11): 1253–83.
  38. Castellagué X., Muñoz N., Pitisuttithum P., Ferris D. G., Monsonego J., Ault K. et al. End­of­study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24­45 years of age. Br. J. Cancer. 2011; 105(1): 28–37.
  39. Ferris D. G. for the FUTURE III Steering Committee. Quadrivalent HPV (types 6/11/16/18) vaccine: end­of­study efficacy against hpv6/11/16/18­related persistent infection and disease in women aged 24 to 45. EUROGIN 2010 Congress. February 17–20, 2010. Monte Carlo; 2010. Abstract SS 3­3.
  40. Joura E. A., Garland S. M., Paavonen J., Ferris D. G., Perez G., Ault K. A. et al. Effect of the human papillomavirus quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial date. BMJ. 2012; 344: 1401.
  41. Kang W. D., Choi H. S., Kim S. M. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high­grade cervical intraepithelial neoplasia (CIN II–III)? Gynecol. Oncol. 2013; 130(2): 264–8.
  42. Descamps D., Hardt K., Spiessens B., Izurieta P., Verstraeten T., Breuer T. et al. Safety of human papillomavirus (HPV)­16/18 AS04­adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials. Hum. Vaccin. 2009; 5(5): 332–40.
  43. Garland S. M., Ault K. A., Gall S. A., Paavonen J., Sings H. L., Ciprero K. L. et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet. Gynecol. 2009; 114(6): 1179–88.
  44. Weekly epidemiological Bulletin of the WHO. Vaccines against human papillomavirus infection human: the document at the position who. 2014; 43(89): 465–92.
  45. Giacomet V., Penagini F., Trabattoni D., Viganò A., Rainone V., Bernazzani G. et al. Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV­infected and HIV­negative adolescents and young adults. Vaccine. 2014; 32(43): 5657–61.
  46. Levin M. J., Moscicki A. B., Song L. Y., Fenton T., Meyer W. A., Read J. S. et al. Safety andimmunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16 and18) vaccine in HIV­infected children 7 to 12 years old. J. Acquir. Immune Defic. Syndr. 2010; 55(2): 197–204.
  47. Grading of scientific evidence HIV. http://www.who.int/immunization/HPV_Grad_HIV.pdf (дата обращения — 15.01.2018).
  48. Краснопольский В. И., Логутова Л. С., Зароченцева Н. В., Белая Ю. М., Тамазян Г. В., Гридчик А. Л. и др. Результаты вакцинопрофилактики ВПЧ­ассоциированных заболеваний и рака шейки матки в Московской области. Рос. вестн. акушера­гинеколога. 2015; 15(3): 9–14. [Krasnopol'skii V. I., Logutova L. S., Zarochentseva N. V., Belaya Yu. M., Tamazyan G. V., Gridchik A. L. i dr. Rezul'taty vaktsinoprofilaktiki VPCh­assotsiirovannykh zabolevanii i raka sheiki matki v Moskovskoi oblasti. Ros. vestn. akushera­ginekologa. 2015; 15(3): 9–14. (in Russian)]
  49. Зароченцева Н. В., Белая Ю. М. Вакцинопрофилактика аногенитальных кондилом в мире и в Московской области. Репродуктивное здоровье детей и подростков. 2017; 2–3: 14–23. [Zarochentseva N. V., Belaya Yu. M. Vaktsinoprofilaktika anogenital'nykh kondilom v mire i v Moskovskoi oblasti. Reproduktivnoe zdorov'e detei i podrostkov. 2017; 2–3: 14–23. (in Russian)]
  50. Дьяков И. А. Фармакоэкономическая эффективность квадривалентной вакцины для профилактики ВПЧ­ассоциированных заболеваний. Мед. совет. 2016; 19: 103–8. [D'yakov I. A. Farmakoekonomicheskaya effektivnost' kvadrivalentnoi vaktsiny dlya profilaktiki VPCh­assotsiirovannykh zabolevanii. Med. sovet. 2016; 19: 103–8. (in Russian)]
Новости мировой медицины! Свежие статьи из журнала! Будьте в курсе!

Похожие статьи

Similar article
19 April 00:00, Interview
Interview
Doctor.Ru Pediatrics. Vol. 20, No. 3 (2021)
19 April 00:00, Paediatrics
A.V. Aksenov, E.A. Ivanovskaya
Successful Use of Tocilizumab in a Child with Systemic Juvenile Idiopathic Arthritis
Doctor.Ru Pediatrics. Vol. 20, No. 3 (2021)

News